Dual PD-1/VEGF blockade in 1L favorable-risk RCC! #DrJunGuo presents ivonescimab (AK112) Ph.Ib/II monotherapy:
ORR 57.1%, DCR 95.2% (n=21 evaluable).
Median PFS NR; grade ≥3 TRAEs 26.9%. Intriguing signal, but small single-arm study and short follow-up.

#ESMO26 #RCC @myESMO @OncoAlert